title: Transfusion of RhD-incompatible blood components in RhD-negative blood marrow transplant recipients.
abstract: BACKGROUND
  Transfusion-dependent bone marrow transplant recipients are routinely transfused with ABO group and RhD-compatible blood components. However, because of the scarcity of RhD-negative blood components, particularly platelets, a policy was developed to transfuse RhD-positive blood components to RhD-negative patients during periods of shortage.
  
  
  METHODS
  We reviewed the records of 78 RhD-negative patients with hematologic malignancies who received RhD-negative bone marrow and/or peripheral blood stem cells, from June 1995 to August 2000. The patients transfused with RhD-incompatible blood components were screened periodically for evidence of the development of red blood cell (RBC) alloimmunization.
  
  
  RESULTS
  Three of 78 patients (4%) developed anti-D antibodies after receiving RhD-incompatible platelet transfusions. One of the patients developed evidence of anti-RhD antibodies after receiving 42 units of RhD-positive random donor platelets; the second patient developed such evidence after receiving 6 apheresis platelets and 2 infusions of intravenous immunoglobulin G (positive for anti-RhD). The third patient received 206 RhD-positive random donor platelets and 5 apheresis units. All patients were discharged from the hospital. The overall immunization rate was 4%. Six patients received Rh-incompatible packed RBCs and showed no evidence of neither anti-RhD nor any other anti-RBC antibodies. All 78 patients had received RhD-incompatible platelets throughout their engraftment period.
  
  
  CONCLUSIONS
  Transfusion of RhD-positive blood components to Rh-negative patients with hematologic cancers, who have received RhD-negative bone marrow and/or peripheral blood stem cells, are at low risk of developing RhD antibodies. These findings allow for a flexible strategy of blood component therapy support for this special patient population during periods of shortage.
authors.affiliation: Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
authors.forename: M
authors.initials: M
authors.lastname: Asfour
authors.forename: Aida
authors.initials: A
authors.lastname: Narvios
authors.forename: Benjamin
authors.initials: B
authors.lastname: Lichtiger
mesh_terms: D000328:Adult; D000368:Aged; D016913:Blood Component Transfusion; D001787:Blood Group Incompatibility; D016026:Bone Marrow Transplantation; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D007518:Isoantibodies / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012204:Rh-Hr Blood-Group System / Q000097:blood* / Q000276:immunology; D018570:Risk Assessment
chemical_list: D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System